Condition: Non-cystic Fibrosis Bronchiectasis · Sponsor: CSL Behring
This study is a phase 2b, multicenter, randomized, double-blind, placebo-controlled, parallel-group, dose range finding study designed to explore the efficacy, safety, and tolerability of 2 active treatment regimens of CSL787 (immunoglobulin G \[IgG\] inhalation solution) compared with placebo over a period of 6 to 12 months independent of the occurrence of pulmonary exacerbations. The primary aim of the study is to characterize the overall effect of CSL787 as well as the dose response of 2 active treatment regimens of inhaled CSL787 administered to participants with NCFB toward prolonging the TTF exacerbation.
This description comes directly from the study's public registry record.
Trial Registration Coordinator · +1 610-878-4697 · clinicaltrials@cslbehring.com
Always discuss trial participation with your own doctor first.
| The Prince Charles Hospital | Queensland, Australia | Recruiting |
| Westmead Hospital | Westmead, Australia | Recruiting |
| Fukuoka University Chikushi Hopsital | Chikushino-shi, Japan | Recruiting |
| Kyusho Central Hospital of the Mutual Aid Association of Public School Teachers | Fukuoka, Japan | Recruiting |
| Ibaraki Prefectural Central Hospital | Ibaraki, Japan | Recruiting |
| Kazunori Tobino Iizuka Hospital | Iizuka-shi, Japan | Recruiting |
| National Hospital Organization Minami Kyoto Hospital | Kyoto, Japan | Recruiting |
| Matsusaka Municipal Hospital | Mie, Japan | Recruiting |
| National Hospital Organization Kinki Chuo Chest Medical Center | Osaka, Japan | Recruiting |
| Shimonoseki City Hospital | Shimonoseki-shi, Japan | Recruiting |
| Japan Anti-Tuberculosis Association, Fukujuji Hospital | Tokyo, Japan | Recruiting |
| Keio University Hospital | Tokyo, Japan | Recruiting |
+ 1 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07048262